Patents by Inventor Jack PUYMIRAT

Jack PUYMIRAT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prostaglandin E2 modulation and uses thereof
    Patent number: 8546077
    Abstract: Methods, uses, kits and products are described for the prognosis, diagnosis, prevention and treatment of myotronic dystrophy type 1 (DM1), and more particularly for the prognosis, diagnosis, prevention and treatment of the congenital form of myotronic dystrophy type 1 (cDM1), based on changes in/modulation of prostaglandin E2 (PGE2).
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: October 1, 2013
    Assignee: Université Laval
    Inventors: Jack Puymirat, Daniel Beaulieu, Pierre Chapdelaine
  • PROSTAGLANDIN E2 MODULATION AND USES THEREOF
    Publication number: 20100304416
    Abstract: Methods, uses, kits and products are described for the prognosis, diagnosis, prevention and treatment of myotronic dystrophy type 1 (DM1), and more particularly for the prognosis, diagnosis, prevention and treatment of the congenital form of myotronic dystrophy type 1 (cDM1), based on changes in/modulation of prostaglandin E2 (PGE2).
    Type: Application
    Filed: June 16, 2010
    Publication date: December 2, 2010
    Inventors: Jack PUYMIRAT, Daniel Beaulieu, Pierre Chapdelaine
  • PROSTAGLANDIN E2 MODULATION AND USES THEREOF
    Publication number: 20090088400
    Abstract: Methods, uses, kits and products are described for the prognosis, diagnosis, prevention and treatment of myotronic dystrophy type 1 (DM1), and more particularly for the prognosis, diagnosis, prevention and treatment of the congenital form of myotronic dystrophy type 1 (cDM1), based on changes in/modulation of prostaglandin E2 (PGE2).
    Type: Application
    Filed: September 5, 2008
    Publication date: April 2, 2009
    Inventors: Jack PUYMIRAT, Daniel Beaulieu, Pierre Chapdelaine